Highly active antiretroviral therapy of similar benefit for HIV-infected injection drug users
Sunday, August 3, 2008 - 13:35
in Health & Medicine
Contrary to the belief that HIV-infected injection drug users (IDUs) receive less benefit from highly active antiretroviral therapy (HAART), new research finds little difference in the survival rate between IDUs and non-IDUs after 4-5 years of receiving HAART, according to a study in the August 6 issue of JAMA, a theme issue on HIV/AIDS.